True North Therapeutics
Biotech · Acquired
Monoclonal antibodies that inhibit the alternative pathway of complement, specifically targeting Factor Bb to treat paroxysmal nocturnal hemoglobinuria and related complement-mediated diseases
- Grants
- $450K
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 14
- 8 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of Monoclonal Antibodies to the Alternative Complement Pathway-Specific Protein Activated Factor B (fBb)as Therapeutics for PNH | $225,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of Monoclonal Antibodies to the Alternative Complement Pathway-Specific Protein Activated Factor B (fBb)as Therapeutics for PNH | $225,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3355 | enGene Holdings | — | — |
| 3356 | Med Aditus Pharmaceuticals, Inc. | — | $5.0M |
| 3357 | CHRONUS PHARMACEUTICALS, INC. | — | — |
| 3358 | True North Therapeutics | — | — |
| 3359 | Neomorph | — | — |
| 3360 | ALPHAMEMORY, LLC | — | — |
| 3361 | CORMEDIX, INC. | — | $3.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- ANTI-COMPLEMENT C1s ANTIBODIES AND METHODS OF INHIBITING COMPLEMENT C1s ACTIVITYgranted
- METHODS OF INHIBITING COMPLEMENT C4 ACTIVATION WITH ANTI-COMPLEMENT C1s ANTIBODIESgranted
- ANTI-COMPLEMENT C1S ANTIBODIES AND METHODS OF INHIBITING COMPLEMENT C1s ACTIVITYgranted
- Methods Of Inhibiting Complement C4 Activation With Anti-complement C1S Antibodiesgranted
- Methods Of Inhibiting Activation Of Complement Component C4 With ANTI-C1S Antibodiesgranted
- METHODS OF INHIBITING ACTIVATION OF COMPLEMENT COMPONENT C4 WITH ANTI-C1s ANTIBODIESgranted
- Anti-complement C1S Antibodiesgranted
- Anti-Complement C1sgranted
- Anti-complement C1S Antibodies And Uses Thereofapplication
- Methods Of Treating Autoimmune And Alloimmune Disordersapplication
- Anti-complement Factor Bb Antibodies And Uses Thereofapplication
- Complement Component Biomarker Assaysapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.